Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesLTR Pharma Ltd

LTR Pharma Ltd

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.42 AUD -0.01 ( 2.33%)
Last update at 2026-11-06T05:10:00Z
VOLUME
17654
Market Cap
78.38M

Momentum Score

…

LTR Pharma Limited, a clinical-stage pharmaceutical company, engages in the research and development of intranasal spray for the treatment erectile dysfunction (ED) in Australia. Its lead product candidate is SPONTAN, an intranasal delivery technology, an oral PDE5 inhibitor and vardenafil HCL for the treatment of ED. The company was incorporated in 2020 and is headquartered in Brisbane, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.42
Low
0.43
High
52 Week Price Range
0.35
Low
0.75
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Public information on LTR Pharma Ltd (LTP.AU) is limited; a clear description of its business, product portfolio and recent filings is not readily accessible. Because verifiable details are sparse, long-term growth drivers cannot be confirmed and investor interest would hinge on future disclosure, demonstrated development or commercial milestones, and the company's ability to raise capital.

Primary risks are likely early-stage or unprofitable operations needing further capital, low market liquidity on the ASX producing volatile trading, and regulatory or clinical-development uncertainty if the firm operates in pharmaceuticals.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.43
Dividend Yield
-
Revenue TTM
0.72M
Revenue Per Share
0.00
Gross Profit TTM
-5.97M
Debt / Equity
-
ROE
-54.73%
Net Debt
-
ROCE
-69.94%
Diluted EPS TTM
-0.08

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax -14.16M -5.59M -6.95M -1.45M -1.03M
Net income -14.16M -5.59M -6.95M -1.45M -1.03M
Selling general administrative 7.08M 4.50M 2.28M 0.46M 0.40M
Gross profit 0.18M - - - -
Reconciled depreciation 0.01M - - - -
Ebit -14.16M - - - -
Ebitda -14.16M - - - -
Operating income -14.53M -5.18M -6.99M -1.44M -1.03M
Interest expense 0.00M - 0.00M 0.00M 0.00M
Tax provision 0.00M 0.00M 0.00M 0.00M 0.00M
Interest income 0.90M -0.08M 0.00M 0.00M 0.00M
Net interest income 0.90M - -0.00M 0.00M 0.00M
Total revenue 0.18M 2.10M - - -
Total operating expenses - 7.28M - - -
Total other income expense net -0.53M - 0.03M -0.02M -0.00M
Net income from continuing ops -14.16M - -6.95M -1.45M -1.03M
Net income applicable to common shares - -5.59M - - -
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 20.85M 32.21M 3.37M 7.51M 2.25M
Other current assets - - - 0.06M 0.04M
Total liab 0.60M 0.70M 0.43M 0.02M 0.48M
Total stockholder equity 20.25M 31.51M 2.94M 7.49M 1.77M
Other current liab 0.37M - 0.19M 0.01M 0.01M
Common stock - 44.11M - - -
Capital stock 44.11M - 10.74M 10.77M 2.79M
Retained earnings -29.24M -12.69M -9.48M -3.86M -1.07M
Cash 19.66M 31.81M 3.10M 7.14M 1.91M
Total current liabilities 0.60M 0.70M 0.43M 0.02M 0.48M
Short term debt - 0.00M - - -
Other stockholder equity - 0.08M - - -
Property plant equipment - 0.01M - - -
Total current assets 20.67M 32.07M 3.37M 7.21M 1.95M
Long term investments 0.17M - - - -
Net receivables 0.03M 0.00M - - -
Inventory 0.57M 0.02M - - -
Accounts payable 0.23M - 0.24M 0.01M 0.47M
Non current assets total 0.18M - 0.00M 0.30M 0.29M
Long term debt total - 0.00M - - -
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments -1.10M - -0.00M -0.00M -
Total cash from financing activities 0.00M 33.37M 6.50M 1.38M 2.34M
Net income -14.16M -5.59M -6.95M -1.45M -1.03M
Change in cash -11.95M 28.74M 1.40M -0.16M 1.78M
Begin period cash flow 31.81M 3.10M 1.73M 1.91M 0.15M
End period cash flow 19.66M 31.81M 3.10M 1.73M 1.91M
Issuance of capital stock - 35.50M 7.00M 1.45M 2.34M
Sale purchase of stock - -2.13M -0.50M -0.07M -
Capital expenditures 0.01M 0.01M 0.00M 0.00M 0.00M
Free cash flow -10.85M -4.45M -5.09M -1.54M -0.57M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
LTP
LTR Pharma Ltd		 -0.01
2.33%		 0.42 - - 108.27 3.69 299.41
CSL
CSL Ltd		 -0.36
0.18%		 202.04 - 22.57 6.15 4.48 4.82
TLX
TELIX Pharmaceuticals Ltd		 -0.41
2.91%		 13.67 93.87 166.67 5.37 6.37 3.85
NEU
Neuren Pharmaceuticals Ltd		 -
-%		 23.24 154.93 36.36 42.38 7.52 31.95
MSB
Mesoblast Ltd		 -0.14
6.45%		 2.03 - 454.55 23.43 3.36 18.28

Profile*

LTR Pharma Ltd

LTR Pharma Limited, a clinical-stage pharmaceutical company, engages in the research and development of intranasal spray for the treatment erectile dysfunction (ED) in Australia. Its lead product candidate is SPONTAN, an intranasal delivery technology, an oral PDE5 inhibitor and vardenafil HCL for the treatment of ED. The company was incorporated in 2020 and is headquartered in Brisbane, Australia.

29/97 Creek Street, Brisbane, QLD, Australia, 4000

61 18 0051 9711

https://ltrpharma.com

Name Title Year Born
Mr. Lee Rodne Executive Chairman NA
Mr. Jacques Schipper Chief Financial Officer NA
Mr. Peter McLennan Chief Operating Officer NA
Ms. Belinda Cleminson BEd, GIA (Cert) Company Secretary NA
Mr. Lee Rodne Executive Chairman NA
Mr. Jacques Schipper Chief Financial Officer NA
Mr. Peter McLennan Chief Operating Officer NA
Ms. Belinda Cleminson BEd, GIA (Cert) Company Secretary NA
Mr. Lee Rodne Executive Chairman NA
Mr. Jacques Schipper Chief Financial Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…